



Common Drug Review *

Submission Status

| | | | |
|----------------------------------|---------------|---------------------------------|---------------|
| Product: | Zytram XL | | |
| Generic Name: | tramadol | | |
| Manufacturer: | Purdue Pharma | | |
| Submission Type: | New | | |
| Date Submission Received: | 2006-Nov-03 | Date NOC Issued: | 2006-Sep-28 |
| Targeted CEDAC Meeting: | 2006-Mar-21 | Priority Review Granted: | Not requested |

| Phase | Target Time (Business Days) | Target Date** | Actual CDR Date | Comments |
|-----------|---|--------------------------------|-----------------|---|
| 1 | Submission Deemed Complete | 5 | 2006-Nov-10 | ACP requested review. Submission withdrawn pending marketing of Zytram XL. |
| 2 | CDR Reviewers' Reports Completed <ul style="list-style-type: none"> • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer | 45 | 2007-Jan-23 | |
| 3 | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7 | 2007-Feb-01 | |
| 4 | Reviewers' Reply to Manufacturer's Comments Completed | 7 | 2007-Feb-12 | |
| 5 | CEDAC Brief Completed and Sent to CEDAC Members | 5 | 2007-Mar-07 | |
| 6 | CEDAC Meeting | | 2007-Mar-21 | |
| 7 | CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer | 5 | 2007-Mar-28 | |
| 8 | Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10 | 2007-Apr-12 | |
| 9 (a) | Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5 | | |
| OR | | | | |
| 9 (b) | Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made) | 5 | | |
| OR | | | | |
| 9 (c) | Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request) | 25 Depends on Meeting Dates | | |
| 10 | Final Recommendation sent to Drug Plans, ACP, and Manufacturer | 5 | | |

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.